vs
Affinity Bancshares, Inc.（AFBI）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Affinity Bancshares, Inc.的1.1倍（$9.1M vs $8.6M），Affinity Bancshares, Inc.净利率更高（24.9% vs -60.3%，领先85.2%），Affinity Bancshares, Inc.同比增速更快（12.8% vs -49.9%），Affinity Bancshares, Inc.自由现金流更多（$11.2M vs $1.6M），过去两年Affinity Bancshares, Inc.的营收复合增速更高（8.1% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
AFBI vs PLX — 直观对比
营收规模更大
PLX
是对方的1.1倍
$8.6M
营收增速更快
AFBI
高出62.7%
-49.9%
净利率更高
AFBI
高出85.2%
-60.3%
自由现金流更多
AFBI
多$9.6M
$1.6M
两年增速更快
AFBI
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.6M | $9.1M |
| 净利润 | $2.1M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 35.9% | -51.1% |
| 净利率 | 24.9% | -60.3% |
| 营收同比 | 12.8% | -49.9% |
| 净利润同比 | 58.5% | -184.8% |
| 每股收益（稀释后） | $0.34 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFBIPLX
| Q4 25 | $8.6M | $9.1M | ||
| Q3 25 | $8.4M | $17.9M | ||
| Q2 25 | $8.3M | $15.7M | ||
| Q1 25 | $7.8M | $10.1M | ||
| Q4 24 | $7.6M | $18.2M | ||
| Q3 24 | $8.0M | $18.0M | ||
| Q2 24 | $8.3M | $13.5M | ||
| Q1 24 | $7.3M | — |
净利润AFBIPLX
| Q4 25 | $2.1M | $-5.5M | ||
| Q3 25 | $2.2M | $2.4M | ||
| Q2 25 | $2.2M | $164.0K | ||
| Q1 25 | $1.8M | $-3.6M | ||
| Q4 24 | $1.3M | $6.5M | ||
| Q3 24 | $1.7M | $3.2M | ||
| Q2 24 | $1.0M | $-2.2M | ||
| Q1 24 | $1.3M | — |
毛利率AFBIPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率AFBIPLX
| Q4 25 | 35.9% | -51.1% | ||
| Q3 25 | 34.9% | 11.9% | ||
| Q2 25 | 34.1% | 7.5% | ||
| Q1 25 | 30.8% | -41.0% | ||
| Q4 24 | 21.1% | 39.6% | ||
| Q3 24 | 28.5% | 22.2% | ||
| Q2 24 | 16.2% | -18.0% | ||
| Q1 24 | 24.0% | — |
净利率AFBIPLX
| Q4 25 | 24.9% | -60.3% | ||
| Q3 25 | 26.5% | 13.2% | ||
| Q2 25 | 25.9% | 1.0% | ||
| Q1 25 | 23.4% | -35.8% | ||
| Q4 24 | 17.7% | 35.6% | ||
| Q3 24 | 21.7% | 18.0% | ||
| Q2 24 | 12.5% | -16.4% | ||
| Q1 24 | 18.2% | — |
每股收益（稀释后）AFBIPLX
| Q4 25 | $0.34 | $-0.06 | ||
| Q3 25 | $0.34 | $0.03 | ||
| Q2 25 | $0.33 | $0.00 | ||
| Q1 25 | $0.28 | $-0.05 | ||
| Q4 24 | $0.21 | $0.10 | ||
| Q3 24 | $0.26 | $0.03 | ||
| Q2 24 | $0.16 | $-0.03 | ||
| Q1 24 | $0.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.9M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $127.0M | $48.2M |
| 总资产 | $881.7M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AFBIPLX
| Q4 25 | $53.9M | $14.7M | ||
| Q3 25 | $84.8M | $13.6M | ||
| Q2 25 | $89.7M | $17.9M | ||
| Q1 25 | $74.7M | $19.5M | ||
| Q4 24 | $41.4M | $19.8M | ||
| Q3 24 | $52.3M | $27.4M | ||
| Q2 24 | $50.4M | $23.4M | ||
| Q1 24 | $61.4M | — |
股东权益AFBIPLX
| Q4 25 | $127.0M | $48.2M | ||
| Q3 25 | $125.4M | $52.9M | ||
| Q2 25 | $124.1M | $49.9M | ||
| Q1 25 | $122.3M | $45.2M | ||
| Q4 24 | $129.1M | $43.2M | ||
| Q3 24 | $128.4M | $32.4M | ||
| Q2 24 | $125.1M | $28.6M | ||
| Q1 24 | $123.3M | — |
总资产AFBIPLX
| Q4 25 | $881.7M | $82.3M | ||
| Q3 25 | $925.2M | $82.3M | ||
| Q2 25 | $933.8M | $78.5M | ||
| Q1 25 | $912.5M | $73.9M | ||
| Q4 24 | $866.8M | $73.4M | ||
| Q3 24 | $878.6M | $61.6M | ||
| Q2 24 | $873.6M | $91.5M | ||
| Q1 24 | $869.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.6M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $11.2M | $1.6M |
| 自由现金流率自由现金流/营收 | 130.9% | 17.8% |
| 资本支出强度资本支出/营收 | 4.9% | 4.4% |
| 现金转化率经营现金流/净利润 | 5.46× | — |
| 过去12个月自由现金流最近4个季度 | $20.3M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流AFBIPLX
| Q4 25 | $11.6M | $2.0M | ||
| Q3 25 | $3.7M | $-3.7M | ||
| Q2 25 | $3.8M | $-5.2M | ||
| Q1 25 | $1.9M | $-5.1M | ||
| Q4 24 | $6.8M | $4.0M | ||
| Q3 24 | $4.1M | $4.1M | ||
| Q2 24 | $619.0K | $-3.6M | ||
| Q1 24 | $1.2M | — |
自由现金流AFBIPLX
| Q4 25 | $11.2M | $1.6M | ||
| Q3 25 | $3.6M | $-4.2M | ||
| Q2 25 | $3.7M | $-5.7M | ||
| Q1 25 | $1.8M | $-5.4M | ||
| Q4 24 | $6.4M | $3.6M | ||
| Q3 24 | $4.0M | $4.0M | ||
| Q2 24 | $489.0K | $-3.8M | ||
| Q1 24 | $1.1M | — |
自由现金流率AFBIPLX
| Q4 25 | 130.9% | 17.8% | ||
| Q3 25 | 43.3% | -23.7% | ||
| Q2 25 | 44.0% | -36.2% | ||
| Q1 25 | 22.7% | -53.0% | ||
| Q4 24 | 83.9% | 19.6% | ||
| Q3 24 | 49.5% | 22.4% | ||
| Q2 24 | 5.9% | -28.1% | ||
| Q1 24 | 14.8% | — |
资本支出强度AFBIPLX
| Q4 25 | 4.9% | 4.4% | ||
| Q3 25 | 0.8% | 2.8% | ||
| Q2 25 | 1.4% | 2.8% | ||
| Q1 25 | 1.9% | 3.0% | ||
| Q4 24 | 5.6% | 2.3% | ||
| Q3 24 | 1.7% | 0.5% | ||
| Q2 24 | 1.6% | 1.3% | ||
| Q1 24 | 1.8% | — |
现金转化率AFBIPLX
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | -1.58× | ||
| Q2 25 | 1.75× | -31.91× | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | 0.61× | ||
| Q3 24 | 2.36× | 1.27× | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFBI
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
